Acadia Pharmaceuticals ACAD announced adding a new phase III development candidate, ACP-101, to its rare disease portfolio. The investigational, intranasal formulation of ACP-101 is set to be ...
The research community has been divided over the effectiveness of calcium phosphate products in remineralizing teeth and reversing caries progression. But evidence supporting the use of amorphous ...
SAN DIEGO & COPENHAGEN, Denmark, March 03, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally ...
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results